VIGNA, ERNESTO
 Distribuzione geografica
Continente #
NA - Nord America 378
EU - Europa 341
AS - Asia 257
AF - Africa 5
SA - Sud America 5
Totale 986
Nazione #
US - Stati Uniti d'America 375
IT - Italia 223
CN - Cina 125
SG - Singapore 123
FI - Finlandia 35
DE - Germania 28
NL - Olanda 15
AT - Austria 14
UA - Ucraina 5
BR - Brasile 4
GB - Regno Unito 4
RU - Federazione Russa 4
CZ - Repubblica Ceca 2
ET - Etiopia 2
JP - Giappone 2
KR - Corea 2
NO - Norvegia 2
PA - Panama 2
SC - Seychelles 2
AR - Argentina 1
CH - Svizzera 1
DK - Danimarca 1
ES - Italia 1
FR - Francia 1
GR - Grecia 1
HK - Hong Kong 1
IE - Irlanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PH - Filippine 1
SE - Svezia 1
ZA - Sudafrica 1
Totale 986
Città #
Florence 136
Boardman 131
Singapore 91
Ashburn 44
Shanghai 42
Helsinki 28
Sesto Fiorentino 22
Noto 20
Munich 13
Washington 12
Vienna 11
Guangzhou 10
Los Angeles 10
Wuhan 9
Lappeenranta 7
Naaldwijk 7
Ogden 7
Amsterdam 6
Beijing 6
Rome 6
Milan 5
Chandler 4
Jinhua 3
Nuremberg 3
Palmi 3
Addis Ababa 2
Ann Arbor 2
Bari 2
Enfield 2
Gualdo Tadino 2
Naples 2
New York 2
Ningbo 2
Oslo 2
San Francisco 2
Seoul 2
Tokyo 2
Turin 2
West Jordan 2
Athens 1
Bishkek 1
Bologna 1
Brasília 1
Brooklyn 1
Cascina 1
Catania 1
Catanzaro 1
Central 1
Chicago 1
Chizhou 1
Cirò Marina 1
Cologne 1
Council Bluffs 1
Des Moines 1
Dublin 1
Falkenstein 1
Frankfurt am Main 1
Guarulhos 1
Hamm 1
Hangzhou 1
Hortolândia 1
Jining 1
Johannesburg 1
Lamezia Terme 1
Lawrence 1
Lianyun 1
Luxembourg 1
Macao 1
Madrid 1
Manila 1
Merlo 1
Mexico City 1
Miami 1
Modigliana 1
Mountain View 1
Pindaí 1
Qingdao 1
Rende 1
Roxbury 1
San Mateo 1
Santa Barbara 1
Santa Clara 1
Seattle 1
Shenzhen 1
Taizhou 1
Tiantai Chengguanzhen 1
Udine 1
Vientiane 1
Yaroslavl 1
Yiwu 1
Zhengzhou 1
Zibo 1
Zurich 1
Totale 718
Nome #
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 48
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 38
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 37
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 32
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 32
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 32
Elotuzumab in multiple myeloma 32
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 30
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 30
Teclistamab-cqyv in multiple myeloma 29
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 28
Belantamab mafodotin in multiple myeloma 28
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 27
Iron chelation therapy 26
Cerebral pheohyphomycosis due to curvularia species 25
Myelodysplastic syndromes with ring sideroblasts 25
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 25
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 25
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 25
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 24
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 23
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 23
Acalabrutinib in chronic lymphocytic leukemia 19
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 19
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 18
Momelotinib in myelofibrosis 18
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 18
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 17
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 16
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 16
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 16
Zanubrutinib for the treatment of chronic lymphocytic leukemia 16
Glasdegib for the treatment of acute myeloid leukemia 15
Ivosidenib in acute myeloid leukemia 15
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 15
Isatuximab in multiple myeloma 14
Selinexor in multiple myeloma 12
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 11
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 11
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 11
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 11
The role of corticosteroids in the current treatment paradigm for myelofibrosis 10
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 10
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 10
Venetoclax in acute myeloid leukemia 10
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 9
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 8
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 8
Mosunetuzumab for the treatment of follicular lymphoma 8
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 7
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 7
Tagraxofusp in myeloid malignancies 7
Avatrombopag for the Treatment of Immune Thrombocytopenia 6
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 6
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 6
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 3
Totale 1.047
Categoria #
all - tutte 11.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.683


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202376 2 0 0 2 1 1 32 3 4 5 20 6
2023/2024536 10 17 105 85 49 64 24 18 17 9 19 119
2024/2025419 48 104 33 65 62 47 24 36 0 0 0 0
Totale 1.047